Erratum: Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: A secondary analysis of the NeoALTTO trial (JAMA Oncology (2015) DOI: 10.1001/jamaoncol.2015.0830);Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: A secondary analysis of the NeoALTTO trial

JAMA Oncology

Volumn 1, Issue 4, 2015, Pages 448-455

  Salgado, Roberto ^a,b   Denkert, Carsten ^c,d   Campbell, Christine ^e   Savas, Peter ^f   Nuciforo, Paolo ^g   Aura, Claudia ^g   De Azambuja, Evandro ^a   Eidtmann, Holger ^h   Ellis, Catherine E ⁱ   Baselga, Jose ^j   Piccart Gebhart, Martine J ^a   Michiels, Stefan ^k   Bradbury, Ian ^e   Sotiriou, Christos ^a   Loi, Sherene ^f  

^a JULES BORDET INSTITUTE   (Belgium)

^b Hospital Gasthuis Zusters Antwerpen (GZA)   (Belgium)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d German Cancer Consortium (DKTK)   (Germany)

^e FRONTIER SCIENCE SCOTLAND LTD   (United Kingdom)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g Val D hebron University Hospital   (Spain)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁱ GLAXOSMITHKLINE   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; LAPATINIB; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TRASTUZUMAB; TUMOR MARKER;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFECTS; ENZYMOLOGY; FEMALE; HUMAN; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; ODDS RATIO; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RETROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, ERBB-2; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TRASTUZUMAB; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84982889739     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.1805     Document Type: Erratum

References (20)

1. Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol.2010;28(1):105-113.
2. Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Res. 2013;73(24 suppl):Abstract S1-05.
3. Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25(8):1544-1550.
4. Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860-867.
5. Adams S, Gray R, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32(27):2959-2966.
6. Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3(12):1355-1363.
7. Rakhra K, Bachireddy P, Zabuawala T, et al. CD4+ T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell. 2010;18(5):485-498.
8. de Azambuja E, Holmes AP, Piccart-Gebhart M, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.Lancet Oncol. 2014;15(10):1137-1146.
9. Baselga J, Bradbury I, Eidtmann H, et al; NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial [published correction appears in Lancet. 2012;379(9816):616]. Lancet. 2012;379(9816):633-640.
10. Majewski I, Nuciforo P, Mittempergher L, et al. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer[published online ahead of print January 5, 2015]. J Clin Oncol.pii:JCO.2014.55.2158.
11. Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. Ann Oncol. 2015;26(2):259-271..
12. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). Breast Cancer Res Treat. 2006;100(2):229-235.
13. Piccart-Gebhart MJ, Holmes AP, Baselga J, et al. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J Clin Oncol. 2014;32(5s):Abstract LBA4.
14. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. 2007;13:1050-1059.
15. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160(1-2):48-61.
16. Loibl S, von Minckwitz G, Schneeweiss A, et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol. 2014;32(29):3212-3220.
17. Denkert C, von Minckwitz G, Brase JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33(9):983-991.
18. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164-172.
19. Bianchini G, Gianni L. The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol. 2014;15(2):e58-e68.
20. Polley MY, Leung SC, McShane LM, et al; International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group. An international Ki67 reproducibility study. J Natl Cancer Inst.2013;105(24):1897-1906.